Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
34 results
D1.242 - Early-Life Dietary Diversity and the Risk of Atopic Dermatitis: A Nationwide Population-Based Cohort Study
D1.244 - Clinical heterogeneity of pediatric atopic dermatitis: latent class analysis
D1.241 - Clinical and Immunological Phenotypes of Alopecia Areata in Children with Atopic Dermatitis
D1.236 - The role of tissue resident memory cells in immunodermatological disorders: A Systematic Review
D1.237 - Mental Health and Neurodevelopmental Comorbidities in Pediatric Atopic Dermatitis: A Retrospective Study and Literature-Based Perspective
D1.238 - Natural history of early onset atopic dermatitis and risk factors for persistency using Korean National Health Service data
D1.239 - Are Maternal Epidermal Lipid Profiles Associated with Atopic Dermatitis Development in Early Childhood?
D1.240 - ATH-409, a selective and covalent ITK inhibitor, protects against atopic dermatitis in preclinical models
D1.245 - The role of advanced glycation end products as facilitating factors in the pathogenesis of atopic dermatitis in pediatric patients
D1.246 - Characterization of Unmet Need for Targeted Precision Medication in Atopic Dermatitis Due to Inadequate Response or Adverse Reactions to Dupilumab
D1.247 - Changes in the sensitization profile in allergic contact dermatitis: comparison between two populations separated by 10 years in a secondary hospital in northern Portugal
D1.248 - Intersection of Autoimmune Mechanisms: Coexistence of Celiac Disease and Chronic Urticaria
D3.440 - Long-Term Efficacy and Safety of Donidalorsen for Hereditary Angioedema Among Patients in Europe: A Regional Analysis of the OASISplus Study
D3.441 - Switching to Donidalorsen for Hereditary Angioedema: 1-Year Results From the Phase 3 OASISplus Study
D3.444 - Efficacy and Safety of Donidalorsen for Patients With Hereditary Angioedema in Europe Who Switched From Prior Long-Term Prophylaxis: Results From the OASISplus Study
D3.445 - Validation of a Novel Serum-Based Indirect Basophil Activation Test (iBAT) to Evaluate Efficacy of a Pivotal Phase III PQ Grass Immunotherapy Trial
D3.437 - Impact of benralizumab on fatigue and health-related quality of life in patients with hypereosinophilic syndrome: findings from the NATRON phase 3 trial
D3.438 - Clinical outcomes with navenibart according to baseline attack rate, body mass index, and age: results of the ALPHA-STAR trial
D3.439 - Donidalorsen For The Treatment Of Hereditary Angioedema: 1-Year Results From The OASISplus Open-Label Extension Cohort
D3.442 - Patient-Reported Outcomes With Long-Term Donidalorsen Treatment Among Patients In Europe With Hereditary Angioedema: 1-Year Interim Results From The OASISplus Open-Label Extension Cohort
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download